After Capturing the U.S. Market, Frost & Sullivan Recognizes Naviscan's Pioneering Organ-Specific PET Scanner's Potential in Europe PR Newswire MOUNTAIN VIEW, California, June 6, 2012 - In addition to high resolution and sensitivity, Naviscan's product provides incomparable workflow integration and economic benefits MOUNTAIN VIEW, California, June 6, 2012 /PRNewswire/ -- Based on its recent analysis of the organ-specific molecular imaging market, Frost & Sullivan recognizes Naviscan Inc. (Naviscan) with the 2012 European Frost & Sullivan Award for Product Quality Leadership for its organ-specific PET scanner. With its main application in Positron Emission Mammography (PEM), the product offers multiple benefits to the customer over competing products. Naviscan's PET scanner offers numerous advantages in a wide variety of clinical applications, such as detection, staging, monitoring response to neo-adjuvant chemotherapy and re-staging of breast cancer, detection of peripheral tumors, and screening for recurrent melanoma. Applications that are showing promise in ongoing clinical trials include osteoarthritis and rheumatoid arthritis. With its ability to position the detectors in close proximity to the organ imaged— achieving higher resolution than a whole-body (WB) PET scanner—the product is simply superior in quality.